| A Coastal Cline in Sodium Accumulation in Arabidopsis thaliana Is Driven by Natural Variation of the Sodium Transporter AtHKT1;1 I Baxter, JN Brazelton, D Yu, YS Huang, B Lahner, E Yakubova, Y Li, ... PLoS genetics 6 (11), e1001193, 2010 | 405 | 2010 |
| Shrinkage estimation of dispersion in Negative Binomial models for RNA-seq experiments with small sample size D Yu, W Huber, O Vitek Bioinformatics 29 (10), 1275-1282, 2013 | 153 | 2013 |
| miR-191 and miR-135 are required for long-lasting spine remodelling associated with synaptic long-term depression Z Hu, D Yu, Q Gu, Y Yang, K Tu, J Zhu, Z Li Nature communications 5 (1), 3263, 2014 | 116 | 2014 |
| Expression of miRNAs and their cooperative regulation of the pathophysiology in traumatic brain injury Z Hu, D Yu, C Almeida-Suhett, K Tu, AM Marini, L Eiden, MF Braga, J Zhu, ... PloS one 7 (6), e39357, 2012 | 99 | 2012 |
| Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia/b study of LY3321367 with or without an anti-PD-L1 antibody JJ Harding, V Moreno, YJ Bang, MH Hong, A Patnaik, J Trigo, ... Clinical Cancer Research 27 (8), 2168-2178, 2021 | 94 | 2021 |
| miR-26a and miR-384-5p are required for LTP maintenance and spine enlargement QH Gu, D Yu, Z Hu, X Liu, Y Yang, Y Luo, J Zhu, Z Li Nature communications 6 (1), 6789, 2015 | 94 | 2015 |
| A phase I study of LY3009120, a pan-RAF inhibitor, in patients with advanced or metastatic cancer RJ Sullivan, A Hollebecque, KT Flaherty, GI Shapiro, J Rodon Ahnert, ... Molecular cancer therapeutics 19 (2), 460-467, 2020 | 81 | 2020 |
| Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced … MW Saif, JA Knost, EG Chiorean, SRP Kambhampati, D Yu, B Pytowski, ... Cancer chemotherapy and pharmacology 78, 815-824, 2016 | 73 | 2016 |
| High-resolution genome-wide scan of genes, gene-networks and cellular systems impacting the yeast ionome D Yu, JMC Danku, I Baxter, S Kim, OK Vatamaniuk, O Vitek, M Ouzzani, ... BMC genomics 13, 1-25, 2012 | 68 | 2012 |
| Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability–high/mismatch repair … A Hollebecque, HC Chung, MJ De Miguel, A Italiano, JP Machiels, CC Lin, ... Clinical Cancer Research 27 (23), 6393-6404, 2021 | 44 | 2021 |
| Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study KA Autio, CA Klebanoff, D Schaer, JSW Kauh, SF Slovin, M Adamow, ... Clinical Cancer Research 26 (21), 5609-5620, 2020 | 41 | 2020 |
| LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose … A Dowlati, RD Harvey, RD Carvajal, O Hamid, SJ Klempner, JSW Kauh, ... Investigational New Drugs 39, 1057-1071, 2021 | 33 | 2021 |
| A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with … A Azaro, C Massard, WD Tap, PA Cassier, J Merchan, A Italiano, ... Investigational new drugs 39, 1089-1098, 2021 | 27 | 2021 |
| Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial A Patnaik, TA Yap, HC Chung, MJ de Miguel, YJ Bang, CC Lin, WC Su, ... Clinical Cancer Research 27 (5), 1267-1277, 2021 | 27 | 2021 |
| Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study NM Tannir, DC Cho, A Diab, M Sznol, MA Bilen, AV Balar, G Grignani, ... Journal for immunotherapy of cancer 10 (4), 2022 | 19 | 2022 |
| Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant … KA Autio, CA Klebanoff, D Schaer, JS Kauh, SF Slovin, VS Blinder, ... Journal of Clinical Oncology 37 (15_suppl), 2548-2548, 2019 | 17 | 2019 |
| Proteomic analysis of high NaCl-induced changes in abundance of nuclear proteins J Li, JD Ferraris, D Yu, T Singh, Y Izumi, G Wang, M Gucek, MB Burg Physiological Genomics, 2012 | 17 | 2012 |
| Noise reduction in genome-wide perturbation screens using linear mixed-effect models D Yu, J Danku, I Baxter, S Kim, OK Vatamaniuk, DE Salt, O Vitek Bioinformatics 27 (16), 2173-2180, 2011 | 15 | 2011 |
| Bempegaldesleukin plus nivolumab in first-line metastatic urothelial carcinoma: results from PIVOT-02 AO Siefker-Radtke, DC Cho, A Diab, M Sznol, MA Bilen, AV Balar, ... European urology 82 (4), 365-373, 2022 | 11 | 2022 |
| A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients. DS Hong, A Hollebecque, MS Gordon, KT Flaherty, G Shapiro, J Rodon, ... Journal of Clinical Oncology 35 (15_suppl), 2507-2507, 2017 | 9 | 2017 |
